SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2013
Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Bisphosphonates and risk of cancers: a systematic review and meta-analysis.British journal of cancer · 2020Pooled it
- Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis.BMJ open · 2015Pooled it
- The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.PloS one · 2015Pooled it
- Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.Scientific reports · 2020Observational
- Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women.Clinical epidemiology · 2019Article
- Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.Current osteoporosis reports · 2017Review
- Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.World journal of gastroenterology · 2016Review
- Carpal Tunnel Syndrome Associated with Oral Bisphosphonates. A Population-Based Cohort Study.PloS one · 2016Article
- Article
- Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study.Journal of bone metabolism · 2015Article
- Oral bisphosphonates and upper gastrointestinal toxicity: a study of cancer and early signals of esophageal injury.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- New strategies for osteoporosis patients previously managed with strontium ranelate.Therapeutic advances in musculoskeletal disease · 2014Review
- How long should we treat?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Review
- Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity.Dento maxillo facial radiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledThe use of bisphosphonates and the risk of esophageal cancer have recently received increasing concern and related studies have yielded controversial results. The present meta-analysis of observational studies shows that no clear association between bisphosphonate treatment and risk of esophageal cancer was observed.
introductionEpidemiological evidence suggests that bisphosphonate treatment can increase the risk of esophageal cancer. However, data on this issue are unstable and controversial. We conducted a meta-analysis to provide a quantitative assessment of the association between use of bisphosphonates and risk of esophageal cancer.
methodsWe searched the Medline and Embase databases up to May 2012 to identify studies related to bisphosphonates and esophageal cancer. Summary effect estimates with 95 % confidence intervals (CI) were derived using a fixed or random effects model, depending on the heterogeneity of the included studies.
resultsSeven epidemiologic studies that consisted of four cohort studies and three case-control studies were included in this meta-analysis. In our primary analysis, bisphosphonate treatment was not associated with risk of esophageal cancer in both cohort studies [pooled relative risk (RR) 1.23, 95 % CI 0.79-1.92] and case-control studies [pooled odds ratio (OR) 1.24, 95 % CI 0.98-1.57]. Evidence for the presence of significant heterogeneity was found in cohort studies (p = 0.009, I (2) = 74 %) but not in case-control studies (p = 0.338, I (2) = 7.8 %). In our secondary analysis, no significant increased risk of esophageal cancer was found in alendronate users (pooled RR 1.08, 95 % CI 0.67-1.75 in cohort studies; pooled OR 1.16, 95 % CI 0.82-1.63 in case-control studies).
conclusionsBased on current evidences, bisphosphonate treatment was not significantly associated with excess risk of esophageal cancer.
Indexed as
Identifiers
23052941What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.